Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.35 |
| ▸ | TLR2 | O60603 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | FAAH | O00519 | 2/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29010635 | 0.82 | TSHR (0.43) | TSHRRECQLHPGDLPAR1TLR2 | |
| SCHEMBL30366355 | 0.81 | MEN1 (0.41) | TSHRRECQLHPGDMEN1KMT2A | |
| SCHEMBL6924528 | 0.80 | RECQL (0.42) | TSHRRECQLHPGDLPAR1MEN1 | |
| SCHEMBL5572365 | 0.79 | TSHR (0.56) | TSHRRECQLHPGDMEN1KMT2A | |
| SCHEMBL18373774 | 0.79 | FAAH (0.55) | RECQLLPAR1MEN1KMT2AFAAH | |
| SCHEMBL19743724 | 0.78 | TLR2 (0.44) | RECQLHPGDTLR2MEN1KMT2A | |
| SCHEMBL8179403 | 0.77 | MEN1 (0.37) | TSHRRECQLHPGDTLR2MEN1 | |
| SCHEMBL5666064 | 0.74 | MEN1 (0.37) | TSHRRECQLHPGDMEN1KMT2A | |
| SCHEMBL2296514 | 0.74 | PHF8 (0.42) | TSHRRECQLMEN1KMT2AALDH1A1 | |
| SCHEMBL8179424 | 0.74 | ALDH1A1 (0.43) | TSHRHPGDMEN1KMT2AMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070149441-A1 | Functionalized derivatives of hyaluronic acid, formation of hydrogels in situ using same, and methods for making and using same | ORTHOGENE LLC (US) | 2007-06-28 | — | — | US | disclosed |
| US-7196180-B2 | Functionalized derivatives of hyaluronic acid, formation of hydrogels in situ using same, and methods for making and using same | ORTHOGENE LLC (US) | 2007-03-27 | — | — | US | disclosed |
| EP-1757314-A1 | Functionalized derivatives of hyaluronic acid, formation of hydrogels and in situ using same | Orthogene L.L.C. (US) | 2007-02-28 | — | — | EP | disclosed |
| EP-1115433-B1 | FUNCTIONALIZED DERIVATIVES OF HYALURONIC ACID, FORMATION OF HYDROGELS AND IN SITU USING SAME | ORTHOGENE L L C (US) | 2004-12-08 | — | — | EP | disclosed |
| US-20040072793-A1 | Functionalized derivatives of hyaluronic acid, formation of hydrogels in situ using same, and methods for making and using same | ORTHOGENE, L L C. | 2004-04-15 | — | — | US | disclosed |
| US-6630457-B1 | Functionalized derivatives of hyaluronic acid, formation of hydrogels in situ using same, and methods for making and using same | ORTHOGENE LLC | 2003-10-07 | — | — | US | disclosed |
| EP-1115433-A1 | FUNCTIONALIZED DERIVATIVES OF HYALURONIC ACID, FORMATION OF HYDROGELS AND IN SITU USING SAME | Orthogene L.L.C. (US) | 2001-07-18 | — | — | EP | disclosed |
| WO-2000016818-A9 | FUNCTIONALIZED DERIVATIVES OF HYALURONIC ACID AND FORMATION OF HYDROGELS IN SITU USING SAME | AESCHLIMANN DANIEL (GB) | 2000-08-24 | — | — | WO | disclosed |
| WO-2000016818-A1 | FUNCTIONALIZED DERIVATIVES OF HYALURONIC ACID AND FORMATION OF HYDROGELS IN SITU USING SAME | ORTHOGENE L.L.C. (US) | 2000-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149441-A1 | Functionalized derivatives of hyaluronic acid, formation of hydrogels in situ using same, and methods for making and using same | CD44, HDGF, HAAO | TSHR 1395/4885RECQL 3598/4885HPGD 62/4885 |
| US-20040072793-A1 | Functionalized derivatives of hyaluronic acid, formation of hydrogels in situ using same, and methods for making and using same | CD44, HDGF, HAAO | TSHR 1395/4885RECQL 3598/4885HPGD 62/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.